Markets

Dipexium Pharmaceuticals (DPRX) Jumps: Stock Rises 7.5%

Dipexium Pharmaceuticals, Inc.DPRX was a big mover last session, as the company saw its shares rise above 7% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up more than 28% in the past one-month time frame.

In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Dipexium Pharmaceuticals currently holds a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.

Another favorably placed Med-Drugs stock is Acerus Pharmaceuticals Corporation TRLPF , which sports a Zacks Rank #1 (Strong Buy).

Is DPRX going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ACERUS PHARMS (TRLPF): Free Stock Analysis Report

DIPEXIUM PHARMA (DPRX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More